Laboratory (LH) Earnings Date & Reports

Key Takeaways

• Total revenue rose 6.9% year over year to $3.81 billion, surpassing the consensus estimate of roughly $3.77 billion.
• Adjusted earnings per share (EPS) climbed 14.5% to $4.78, ahead of the approximately $4.65 consensus forecast.
• Both the Diagnostics Laboratories and Biopharma Laboratory Services segments grew, and management raised its full-year 2026 guidance.
• Free cash flow improved to $412 million from $281 million in the prior-year quarter.
• A proposed Medicare fee-schedule change under PAMA (the Protecting Access to Medicare Act) could create an estimated $125 million reimbursement headwind in 2027.
• For more on Labcorp's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Looking for automated market ideas? Explore Trending AI Robots.

Earnings Context and Why It Matters

Labcorp Holdings Inc. (LH), one of the largest clinical laboratory networks in the world, sits at the intersection of routine diagnostics and high-growth specialty testing. Its quarterly results are a useful barometer for healthcare utilization and pharmaceutical research spending. Heading into this report, investors were focused on whether organic volume growth and margin expansion could continue while management navigates acquisition integration and reimbursement policy uncertainty. The third quarter delivered a sixth consecutive quarter of enterprise margin progression, supported by volume gains and productivity initiatives. Strong demand in central laboratory services and specialty testing reinforced the company's strategic shift toward oncology, neurology, and women's health, while a proposed Medicare fee-schedule change added a new layer of risk for 2027.

Reported Results

Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from $3.56 billion a year earlier, exceeding the consensus estimate by about 1%. Organic revenue growth was 5.5%, with acquisitions contributing 1.5% and foreign currency translation a slight 0.1% drag.

Adjusted EPS rose 14.5% to $4.78, above the roughly $4.65 consensus estimate. On a GAAP (generally accepted accounting principles) basis, diluted EPS was $3.22, compared with $3.12 in the prior-year quarter.

By segment, Diagnostics Laboratories revenue increased 6.5% to $2.95 billion, driven by 3.1% organic volume growth and 1.3% favorable price and mix. Biopharma Laboratory Services (BLS) revenue advanced 8.5% to $866.7 million, with central labs growing 11.5%. Enterprise adjusted operating margin expanded 60 basis points to 15%. Management also raised full-year 2026 guidance, lifting revenue growth expectations to 5.9%–6.7% and adjusted EPS guidance to $18.30–$18.70.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring healthcare names like Labcorp, it offers a structured way to surface ideas across sectors. Explore the AI Screener to see how it can support your research process.

Market Reaction and Investor Sentiment

Labcorp shares rose roughly 1.4% to 1.5% in pre-market trading following the announcement, reflecting a favorable response to the earnings beat and the raised full-year outlook. Investors appeared to weigh the strength in both segments and improved free cash flow against the emerging reimbursement risk tied to proposed PAMA fee-schedule changes. Management expressed disappointment with the preliminary fee schedule, which relies on data from a small subset of laboratories, and cautioned that the proposed cuts could pressure patient access and industry viability. The reaffirmed long-term outlook, combined with continued margin progression, helped temper concerns heading into the session.

Forward Outlook and Key Factors to Monitor

Several factors will shape Labcorp's trajectory following this report. First, investors will watch how the proposed PAMA reimbursement changes evolve, given management's estimate of a roughly $125 million impact in 2027. The company has signaled support for the RESULTS Act and continues to engage on policy, but the final fee schedule remains a key variable.

Second, integration of recently announced acquisitions will matter. Agreements involving select BioReference Health assets, Myriad Genetics' prenatal health testing business, and Millennium Health are expected to strengthen specialty testing and drug-testing capabilities. Their contribution to growth and margins, and the timing of regulatory approvals, will be closely monitored.

Finally, demand trends in specialty testing, central laboratory bookings, and the performance of the company's LaunchPad productivity initiative will be important indicators of whether margin expansion and double-digit EPS growth can be sustained. Management reaffirmed its 2026–2029 long-term outlook, but execution against that framework will depend on balancing growth, cost discipline, and reimbursement policy outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations